Published in Parasitol Res on March 30, 2006
The parasite clearance curve. Malar J (2011) 4.30
Establishing a malaria diagnostics centre of excellence in Kisumu, Kenya. Malar J (2007) 2.33
Changing patterns of Plasmodium blood-stage infections in the Wosera region of Papua New Guinea monitored by light microscopy and high throughput PCR diagnosis. Am J Trop Med Hyg (2006) 1.93
Pilot assessment of the sensitivity of the malaria thin film. Malar J (2008) 1.37
Comparison of an assumed versus measured leucocyte count in parasite density calculations in Papua New Guinean children with uncomplicated malaria. Malar J (2014) 1.07
Evaluation of a novel magneto-optical method for the detection of malaria parasites. PLoS One (2014) 1.06
Molecular test for vivax malaria with loop-mediated isothermal amplification method in central China. Parasitol Res (2011) 0.93
Comparison of three methods for detection of gametocytes in Melanesian children treated for uncomplicated malaria. Malar J (2014) 0.89
Maternal malaria, birth size and blood pressure in Nigerian newborns: insights into the developmental origins of hypertension from the Ibadan growth cohort. PLoS One (2011) 0.84
Comparison of PfHRP-2/pLDH ELISA, qPCR and microscopy for the detection of plasmodium events and prediction of sick visits during a malaria vaccine study. PLoS One (2013) 0.83
Statistical properties of parasite density estimators in malaria. PLoS One (2013) 0.81
Evaluating the effectiveness of IPTi on malaria using routine health information from sentinel health centres in southern Tanzania. Malar J (2011) 0.79
A method for reducing the sloughing of thick blood films for malaria diagnosis. Malar J (2013) 0.77
Parasite Specific Antibody Increase Induced by an Episode of Acute P. falciparum Uncomplicated Malaria. PLoS One (2015) 0.75
A comparative study of thick and thin blood films in the diagnosis of scanty malaria parasitaemia. Bull World Health Organ (1966) 5.85
Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. J Infect Dis (2005) 4.44
Comparison of two simple methods for determining malaria parasite density. Trans R Soc Trop Med Hyg (1991) 3.94
White blood cell counts and malaria. J Infect Dis (2005) 3.46
Reliability of malaria microscopy in epidemiological studies: results of quality control. Trop Med Int Health (2000) 2.90
What is clinical malaria? Finding case definitions for field research in highly endemic areas. Parasitol Today (1994) 2.90
Sources of variability in determining malaria parasite density by microscopy. Am J Trop Med Hyg (2005) 2.34
Impact of transmission intensity and age on Plasmodium falciparum density and associated fever: implications for malaria vaccine trial design. J Infect Dis (1995) 1.19
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med (2011) 10.79
Assessment of inpatient paediatric care in first referral level hospitals in 13 districts in Kenya. Lancet (2004) 7.13
A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med (2012) 6.64
Revisiting the basic reproductive number for malaria and its implications for malaria control. PLoS Biol (2007) 5.40
Statics and dynamics of malaria infection in Anopheles mosquitoes. Malar J (2004) 4.65
Delivery of paediatric care at the first-referral level in Kenya. Lancet (2004) 4.16
The risk of a mosquito-borne infection in a heterogeneous environment. PLoS Biol (2004) 3.46
Burden, features, and outcome of neurological involvement in acute falciparum malaria in Kenyan children. JAMA (2007) 3.29
The multiplicity of malaria transmission: a review of entomological inoculation rate measurements and methods across sub-Saharan Africa. Malar J (2009) 2.66
Ross, macdonald, and a theory for the dynamics and control of mosquito-transmitted pathogens. PLoS Pathog (2012) 2.38
Sources of variability in determining malaria parasite density by microscopy. Am J Trop Med Hyg (2005) 2.34
Establishing a malaria diagnostics centre of excellence in Kisumu, Kenya. Malar J (2007) 2.33
An elaborated feeding cycle model for reductions in vectorial capacity of night-biting mosquitoes by insecticide-treated nets. Malar J (2007) 2.33
A simulation model of African Anopheles ecology and population dynamics for the analysis of malaria transmission. Malar J (2004) 2.29
Gametocytogenesis: the puberty of Plasmodium falciparum. Malar J (2004) 2.29
Relationship between exposure, clinical malaria, and age in an area of changing transmission intensity. Am J Trop Med Hyg (2008) 2.29
Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine (2005) 2.18
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. N Engl J Med (2015) 2.03
The unexpected importance of mosquito oviposition behaviour for malaria: non-productive larval habitats can be sources for malaria transmission. Malar J (2005) 1.93
Hypothetical performance of syndrome-based management of acute paediatric admissions of children aged more than 60 days in a Kenyan district hospital. Bull World Health Organ (2003) 1.87
Global sequence variation in the histidine-rich proteins 2 and 3 of Plasmodium falciparum: implications for the performance of malaria rapid diagnostic tests. Malar J (2010) 1.77
A controlled, parallel, cluster-randomized trial of community-wide screening and treatment of asymptomatic carriers of Plasmodium falciparum in Burkina Faso. Malar J (2013) 1.73
Potential impact of intermittent preventive treatment (IPT) on spread of drug-resistant malaria. PLoS Med (2006) 1.72
Reader technique as a source of variability in determining malaria parasite density by microscopy. Malar J (2006) 1.68
Incidence and outcome of convulsive status epilepticus in Kenyan children: a cohort study. Lancet Neurol (2008) 1.55
Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems. Lancet Infect Dis (2012) 1.53
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg (2014) 1.51
Using the entomological inoculation rate to assess the impact of vector control on malaria parasite transmission and elimination. Malar J (2010) 1.49
In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. Antimicrob Agents Chemother (2006) 1.46
The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J (2013) 1.41
The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether-lumefantrine: a review of the evidence. Malar J (2008) 1.40
CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine. Malar J (2012) 1.39
Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine. Malar J (2011) 1.38
Pilot assessment of the sensitivity of the malaria thin film. Malar J (2008) 1.37
Environmental factors associated with the malaria vectors Anopheles gambiae and Anopheles funestus in Kenya. Malar J (2009) 1.36
Implementation of a structured paediatric admission record for district hospitals in Kenya--results of a pilot study. BMC Int Health Hum Rights (2006) 1.34
Effective treatment of uncomplicated Plasmodium falciparum malaria with azithromycin-quinine combinations: a randomized, dose-ranging study. Am J Trop Med Hyg (2006) 1.29
Impregnated netting slows infestation by Triatoma infestans. Am J Trop Med Hyg (2008) 1.29
Malaria vaccine efficacy: the difficulty of detecting and diagnosing malaria. Malar J (2007) 1.29
Parasite prevalence: a static measure of dynamic infections. Am J Trop Med Hyg (2007) 1.27
Age-structured red blood cell susceptibility and the dynamics of malaria infections. Proc Natl Acad Sci U S A (2004) 1.25
The spatial and temporal patterns of falciparum and vivax malaria in Perú: 1994-2006. Malar J (2009) 1.25
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. Antimicrob Agents Chemother (2009) 1.21
Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty. Malar J (2010) 1.20
The promise and potential challenges of intermittent preventive treatment for malaria in infants (IPTi). Malar J (2005) 1.18
Misclassification of Plasmodium infections by conventional microscopy and the impact of remedial training on the proficiency of laboratory technicians in species identification. Malar J (2013) 1.18
Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated Plasmodium falciparum malaria in adults: a randomized, phase 2 clinical trial in Thailand. Clin Infect Dis (2006) 1.17
Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). Malar J (2011) 1.12
Impact, challenges, and future projections of vaccine trials in Africa. Am J Trop Med Hyg (2013) 1.10
The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria. Trop Med Int Health (2010) 1.07
Community and facility-level engagement in planning and budgeting for the government health sector--a district perspective from Kenya. Health Policy (2010) 1.07
Nigeria Anopheles vector database: an overview of 100 years' research. PLoS One (2011) 1.05
Host control of malaria infections: constraints on immune and erythropoeitic response kinetics. PLoS Comput Biol (2008) 1.05
Experience and challenges from clinical trials with malaria vaccines in Africa. Malar J (2013) 1.01
Ecological theory to enhance infectious disease control and public health policy. Front Ecol Environ (2005) 0.99
Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki. Ther Clin Risk Manag (2008) 0.99
Review: Improving the therapeutic index of 8-aminoquinolines by the use of drug combinations: review of the literature and proposal for future investigations. Am J Trop Med Hyg (2011) 0.98
Spatial patterns in discordant diagnostic test results for Chagas disease: links to transmission hotspots. Clin Infect Dis (2009) 0.98
Use of a rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances. Am J Trop Med Hyg (2012) 0.97
Coupling ecology and evolution: malaria and the S-gene across time scales. Math Biosci (2004) 0.96
Link between immune response and parasite synchronization in malaria. Proc Natl Acad Sci U S A (2003) 0.95
Rational spatio-temporal strategies for controlling a Chagas disease vector in urban environments. J R Soc Interface (2010) 0.95
Competition for red blood cells can enhance Plasmodium vivax parasitemia in mixed-species malaria infections. Am J Trop Med Hyg (2006) 0.93
Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy. Antimicrob Agents Chemother (2010) 0.93
Antimalarial activity of novel 5-aryl-8-aminoquinoline derivatives. J Med Chem (2010) 0.92
Sample-ready multiplex qPCR assay for detection of malaria. Malar J (2014) 0.91
Humanized mouse model of glucose 6-phosphate dehydrogenase deficiency for in vivo assessment of hemolytic toxicity. Proc Natl Acad Sci U S A (2013) 0.91
Data safety and monitoring boards for African clinical trials. Trans R Soc Trop Med Hyg (2008) 0.90
African Burkitt's lymphoma: could collaboration with HIV-1 and malaria programmes reduce the high mortality rate? Lancet (2010) 0.89
Malaria mortality estimates: need for agreeable approach. Trop Med Int Health (2012) 0.88
Absolute bioavailability of cis-mirincamycin and trans-mirincamycin in healthy rhesus monkeys and ex vivo antimalarial activity against Plasmodium falciparum. Antimicrob Agents Chemother (2011) 0.87
HIV-1 subtype diversity based on envelope C2V3 sequences from Kenyan patients on highly active antiretroviral therapy. AIDS Res Hum Retroviruses (2014) 0.85
Host immune constraints on malaria transmission: insights from population biology of within-host parasites. Malar J (2013) 0.85
Haemoglobin dynamics in Papuan and non-Papuan adults in northeast Papua, Indonesia, with acute, uncomplicated vivax or falciparum malaria. Malar J (2013) 0.84
Tolerability of azithromycin as malaria prophylaxis in adults in northeast papua, indonesia. Antimicrob Agents Chemother (2003) 0.84
A randomized, double-blind, safety and tolerability study to assess the ophthalmic and renal effects of tafenoquine 200 mg weekly versus placebo for 6 months in healthy volunteers. Am J Trop Med Hyg (2009) 0.84
Nelfinavir and its active metabolite, hydroxy-t-butylamidenelfinavir (M8), are transferred in small quantities to breast milk and do not reach biologically significant concentrations in breast-feeding infants whose mothers are taking nelfinavir. Antimicrob Agents Chemother (2011) 0.83
The impact of clinical research activities on communities in rural Africa: the development of the Clinical Research Unit of Nanoro (CRUN) in Burkina Faso. Malar J (2014) 0.83
Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects. Br J Clin Pharmacol (2013) 0.83
Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges. Malar J (2011) 0.82
Evaluation of recurrent parasitemia after artemether-lumefantrine treatment for uncomplicated malaria in children in western Kenya. Am J Trop Med Hyg (2010) 0.82
Developmental allometry and paediatric malaria. Malar J (2012) 0.82
Antimalarial activity of 9a-N substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin. J Med Chem (2012) 0.82
Ruthenium-catalyzed selective hydrogenation of benzene to cyclohexene in the presence of an ionic liquid. Angew Chem Int Ed Engl (2011) 0.81
Plasmodium falciparum infection during suppressive prophylaxis with mefloquine does not induce an antibody response to merozoite surface protein-1(42). Am J Trop Med Hyg (2011) 0.81
Decorticate, decerebrate and opisthotonic posturing and seizures in Kenyan children with cerebral malaria. Malar J (2005) 0.81
The presence of Plasmodium falciparum gametocytes in human blood increases the gravidity of Anopheles gambiae mosquitoes. Am J Trop Med Hyg (2005) 0.81
High-performance supported catalysts with an ionic liquid layer for the selective hydrogenation of acetylene. Chem Commun (Camb) (2011) 0.81
Genotypic Variability of HIV-1 Reverse Transcriptase Gene from Long-Term Antiretroviral-Experienced Patients in Kenya. AIDS Res Hum Retroviruses (2015) 0.80